Oesophageal cancer in Area 2 of Kwazulu-Natal: predictors of late presentation. by Ferndale, L et al.
LSHTM Research Online
Ferndale, L; Sartorius, B; Aldous, C; Thomson, SR; (2019) Oesophageal cancer in Area 2 of Kwazulu-
Natal: predictors of late presentation. South African journal of surgery. Suid-Afrikaanse tydskrif vir
chirurgie, 57 (2). pp. 4-9. ISSN 0038-2361 https://researchonline.lshtm.ac.uk/id/eprint/4654184
Downloaded from: http://researchonline.lshtm.ac.uk/4654184/
DOI:
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/3.0/
https://researchonline.lshtm.ac.uk
4 SAJS  VOL. 57 NO. 2  JUNE 2019      
Introduction
Oesophageal cancer is the eighth most common cancer in 
the world.1 The highest incidence is reported in East and 
South-East Asia. Sub-Saharan Africa has the second highest 
incidence worldwide.1, 2 The estimated Age Standardised 
Rate (ASR) in Southern Africa is 13.7 and 6.7 per 100 000 
in men and women respectively.1 Squamous cell carcinoma 
and adenocarcinoma are the two main histological subtypes.2 
The former is the predominant subtype in South Africa where 
the Eastern Cape has the highest documented incidence.3-5 
Oesophageal squamous cell carcinoma (OSCC) is generally 
associated with a poor prognosis.6 This is particularly true 
in South Africa where most patients with oesophageal 
cancer present late with debilitating symptoms and incurable 
disease.7,8 The majority of patients are not suitable for curative 
treatment at the time of diagnosis.6,9 This disease can have a 
devastating effect on quality of life and five-year survival is 
low.4,10 
Retrospective studies provide limited information on 
the patient profile, clinical presentation and treatment of 
squamous cell carcinoma of the oesophagus in KwaZulu-
Natal (KZN). Many of these studies are based only on patients 
who reach health institutions and reflect the referral bias due 
to limited and regionally variable access to more sophisticated 
levels of care. Epidemiological studies are hampered by lack 
of awareness of the symptoms of the disease as well as the 
variable data sets coming from sub-Saharan Africa.1,11,12 
Consequently it is probable that the incidence of oesophageal 
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squamous cell carcinoma may be underestimated in the 
region and that a lack of awareness of this disease may be 
contributing to the late presentation and poor prognosis.
To gain a better understanding of the clinical profile of 
patients diagnosed with OSCC and the frequency of factors 
associated with advanced disease at the time of diagnosis 
we prospectively collected and analysed data from patients 
presenting to a tertiary hospital in KZN. 
Methods
Study design
This study employed a prospective case series design. All 
patients with a suspected or confirmed diagnosis of OSCC 
presenting to Greys Hospital between April 2016 and March 
2017 were entered into the study. Greys hospital is a tertiary 
hospital in KZN providing care to patients from Area 2, 
which is a large area comprising urban and rural populations 
covering the western part of KZN, with a population of about 
three million and 20 referring hospitals.13,14 Data collected 
included demographic data, symptom severity, body mass 
index (BMI), serum albumin levels, performance status, 
tumour pathology and treatment administered. Significant 
weight loss was defined as weight loss resulting in a change 
in the size of the clothing they could wear comfortably. The 
BMI was defined as normal if it was between 18.5 and 25. 
A BMI above 25 was classified as overweight and below 
18.5 as underweight. A BMI of less than 16 was classified 
as severely underweight. Patients in whom the diagnosis of 
OSCC could not be confirmed histologically were excluded 
from the analysis.
We assessed severity of dysphagia using the Mellow and 
Pinkas dysphagia score.15 This is a 5-scale grading system 
where grade 0 denotes the ability to swallow normally: grade 
1 dysphagia to normal solids, grade 2 dysphagia to soft solids, 
grade 3 dysphagia to liquids and solids and grade 4 inability 
to swallow saliva. 
Performance status was measured using the Eastern 
Cooperative Oncology Group score16 as follows; Grade 0 
– fully active with no physical restrictions; Grade 1 – some 
physical restriction but able to carry out light work; Grade 2 
– ambulatory and capable of self-care but unable to carry out 
any work activity, confined to bed or wheelchair less than 50% 
of waking hours; Grade 3 – capable of only limited self-care, 
confined to bed or wheelchair for more than 50% of waking 
hours; Grade 4 – completely disabled, unable to carry out any 
self-care, totally confined to bed or chair. 
A decision on whether to treat a patient palliatively or with 
curative intent was made based on a combination of clinical, 
pathological and imaging criteria. Criteria for palliative 
management were age > 70 years, co-morbidities precluding 
major surgery, ECOG status >1, serum albumin < 25g/l, 
tumour length > 8 cm or advanced tumour stage.
Statistical analysis
Data were processed and analysed using Stata 13.0 (StataCorp, 
2013). Continuous variables were summarised using mean 
and standard deviation or median and interquartile range if 
evidence of skewing or asymmetrical outliers. 
Results
Demographics
One hundred and eight patients were entered into the database 
over the study period. Eight patients were excluded from 
analysis: two had adenocarcinoma and six had no histological 
diagnosis. There were 59 males and 41 females and the mean 
age was 61 years (SD = 12.8) The overall ASR (95%CI) was 
25.2 per 100 000. It was 29.1 in males and 17.2 in females. 
All patients were African with 94% first language isiZulu. 
The majority of patients (70%) were referred from the 
three regional hospitals that fall within the drainage area of 
Greys hospital. The remainder of the referrals were equally 
distributed amongst the rural district hospitals and one patient 
was from outside area 2. The patient characteristics are 
summarised in Table 1. 
Clinical characteristics
Clinical characteristics of the patient cohort are shown in Table 
2. Of the 100 patients analysed, dysphagia was the primary 
presenting symptom in 97% of patients with 44% reporting 
grade 3 or 4 dysphagia. Sixty percent reported significant 
weight loss. BMI could be calculated in 94 patients. The 
median BMI was 20.0 (range 11–45) and 49% of patients had 
a low BMI at presentation. Furthermore, 19% were severely 
underweight (BMI < 16 kg/m2). The majority of patients 
Figure 1. Referral centres from Area 2 (Greys catchment area)
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(70%) were hypoalbuminaemic (serum albumin < 35 g/l) at 
the time of presentation. The median serum albumin level 
was 30 g/l (range 13–42). Only four out of 90 patients had a 
normal ECOG performance status, while 50% of patients had 
a performance status poorer than ECOG 1.
Pathology and treatment
The mean tumour length was 6.4 cm (SD = 3.5) and the 
majority (72%) were moderately differentiated with only 8% 
being well-differentiated. Ninety percent of patients were 
treated palliatively. Five percent were treated surgically and 
five percent declined treatment, could not be palliated or were 
lost to follow-up. Self-expanding metal stents (SEMS) were 
inserted in 82 of 90 patients selected for palliative treatment. 
The other forms of palliation used included chemoradiotherapy 
in two patients and serial oesophageal dilatation in six. Details 
of patients that fulfilled the criteria for palliative management 
are shown in Table 3. A number of patients had more than one 
indication for palliative management.
The factors that indicate a late presentation and their 
frequencies are shown in Table 4.
Discussion
Our study indicates that OSCC is a significant health care 
problem in KwaZulu-Natal. The fact that all of the 100 
patients collected over a one-year period were African 
underscores the burden this disease puts on this particular 
population group. Our ASR of 25 is higher than the recorded 
incidence in South Africa,17 indicating that the disease may 
be under-reported nationally. The mean age of 61 years is in 
keeping with reports in the published literature. Our male to 
female ratio of 1.5:1 also shows a similar male preponderance 
to other regions of Africa (1.6:1) but much lower than the 3:1 
ratio reported from other regions of the world.1,8,18 
We have identified a number of factors that are associated 
with late presentation and diagnosis at an advanced stage, 
which is a world-wide problem, but seems to be a particular 
problem in our patient population.19,20,21 Dysphagia indicates 
a more advanced T-stage of oesophageal cancer.21,22,23 The 
Table 1: Cohort Characterisation
Characteristic N = 100
Mean age in years (range) 61 (32-93)
M:F 1.5:1
59:41
Race
African 100
Home language
Zulu 94
English 4
Xhosa 2
Level of referral centre
      Regional 70
     District 29
Outside drainage area 1
Table 2: Frequency of the clinical and biochemical assessment 
parameters
Assessment parameter Number
Dysphagia score N = 100
0 3
1 29
2 24
3 36
4 8
ECOG status N  = 90
0 4
1 38
2 27
3 18
4 3
Body Mass Index N = 94
Severely underweight (<16kg/m2) 17
Underweight (16-18.4kg/ m2) 29
Normal (18.5-24.9kg/ m2) 34
        Overweight (>/=25kg/m2) 14
Serum Albumin g/l N = 92
< 30 40
        30 – 35 25
        >35 27
Table 3: Criteria for palliative management 
Criterion for palliative management Number of patients
Age >70 years 23
Prohibitive co-morbidities 5
Serum Albumin<25g/l 17
ECOG >/= 2 48
Tumour length > 8cm 37
Advanced tumour stage 4
Table 4: Frequency of indicators of late presentation
Indicator Percentage of patients
Dysphagia grade >/= 2 68
BMI </=18.5 53
Serum Albumin<35g/l 70
ECOG >/= 2 50
Degree of tumour differentiation – 
Moderate to severe
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prevalence of dysphagia (97%) and advanced grade (44% 
with grade 3 or 4 dysphagia) was particularly striking. 
Secondly, a history of weight loss, low body mass index 
and low serum albumin, factors often used in combination 
to identify patients with malnutrition, were present in the 
majority of our patients.24 A low BMI has been shown to have 
a negative impact on survival and may even increase the risk 
of developing OSCC.25,26,27 These paramaters, alone or in 
combination, also impact on prognosis, and predict response 
to chemo-radiotherapy.28, 29,30 Thirdly, patients with an ECOG 
status 0 made up only 4% of the cohort, a proportion much 
lower than reported in the literature.31 The last indicator of late 
presentation among our patients is the degree of differentiation 
on pathological assessment. The degree of differentiation 
has been shown to be a risk factor for poor prognosis at an 
advanced stage32,33 and more than 80% of our patients had 
moderately to poorly differentiated tumours.
The abovementioned factors culminated in only 5% of 
patients in our series being offered potentially curative 
treatment, a figure much lower than reported by others.6,34 In 
the context, it is reassuring that placement of self-expanding 
metal stent which is considered the standard of care in 
palliation of dysphagia was available and could be performed 
in 90% of patients who were palliated.35,36  Table 5 highlights 
the paucity and variability of data points we have identified as 
indicators of late presentation in oesophageal cancer in other 
series.
The drivers of late presentation in our patient population 
need further investigation. Some patients seek help from 
traditional healers before presenting to hospital, with socio-
economic factors given as the main reason given by the 
remainder.7 Whereas patients factors are a major contributor to 
delay, the lack of knowledge among health care workers and 
lack of clear care pathways in the health care system probably 
also contribute to delay in diagnosis and treatment. These 
factors need to be quantified in order to devise strategies to 
address the problem.
Conclusion 
Our data show a higher incidence of oesophageal cancer than 
expected and that patients with oesophageal cancer in our 
population have a poorer prognosis than patients with the 
same diagnosis elsewhere. Potential interventions to improve 
outcomes are population and health care worker education 
particularly around the recognition of dysphagia as an alarm 
symptom and the need for urgent endoscopic evaluation. 
This would include streamlining of referral patterns and 
monitoring times from presentation to diagnosis, assessment 
and treatment. Implementation would require a coordinated 
research agenda not simply addressing health systems research 
but also epidemiological and basic science approaches to 
better understand the diseases aetiopathogenesis with a view 
to the possible introduction of screening strategies. 
The study was approved by the Biomedical Research 
Ethics Committee of University of KwaZulu-Natal (ref. no. 
BF270/15).
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